Research never stops


Nov 10, 2011

Nine months results: Upside materialising

Oct 27, 2011

Two Milestones in Fragment-based Drug Discovery Alliance with Shionogi achieved

Oct 20, 2011

Evotec and APEIRON Biologics start next project on the Cbl-b target

Oct 05, 2011

Second multi-target collaboration with UCB announced

Sep 29, 2011

Acquisition of remaining 30% of Indian Joint Venture from DIL

Sep 05, 2011

Evotec and Roche agree to develop compound that could slow the progression of Alzheimer's disease

Aug 18, 2011

Pre-clinical Milestone Payment as Part of its Discovery Alliance with Boehringer Ingelheim received

Aug 11, 2011

Evotec reports 34% revenue and profitable earnings growth; revenue guidance raised

Aug 11, 2011

P2X7 antagonist programme, EVT 401, to a top tier global animal health company partnered

Jul 07, 2011

Multi-target collaboration with UCB in neurodegenerative and neurological diseases announced

Jun 27, 2011

Milestone in an Ion Channel Drug Discovery Collaboration with Ono Pharmaceutical Co., Ltd. achieved

Jun 24, 2011

Evotec and Roche to jointly develop biomarkers in oncology

Jun 06, 2011

Medicinal Chemistry Collaboration with Active Biotech

Jun 01, 2011

Compound management business from Galapagos acquired

May 31, 2011

Milestone received as Boehringer Ingelheim starts Phase I clinical trial in Pain

May 25, 2011

Strategic Alliance with PsychoGenics entered to Provide Integrated CNS Drug Discovery Solutions

May 18, 2011

Phase II study with NR2B sub-type selective NMDA antagonist in treatment-resistant depression voluntarily terminated

May 12, 2011

Evotec reports 54% Q1 revenue growth and significant expansion of drug discovery alliance business

May 09, 2011

Twelfth Milestone Payment as Part of its Discovery Alliance with Boehringer Ingelheim received

Apr 19, 2011

Acquisition of Kinaxo Biotechnologies GmbH completed

Mar 24, 2011

Full-Year 2010 Results: A good year with a strong start into 2011

Mar 10, 2011

Evotec Establishes Research Collaboration With Harvard University and the Howard Hughes Medical Institute in Diabetes Research

Feb 15, 2011

Evotec to Strengthen its Compound Collection through a Collaboration with ChemBridge

Feb 09, 2011

Expanding its drug discovery platform with cutting-edge technologies

Jan 20, 2011

Collaboration with Takeda Cambridge for Multi-target Hit Identification

Jan 13, 2011

Milestone Payment received from Boehringer Ingelheim

Jan 04, 2011

Evotec deregisters from the US Securities and Exchange Commission